Patent protection expirey for stendra?

Stendra (avanafil) – Patent Status (as of 2026)

Key Take‑aways

1. Core patents covering the active ingredient and its method of treating erectile dysfunction (ED) have long since expired.

   • The earliest patents that protected avanafil’s composition and use expired between 2015 and 2019.

2. Formulation‑specific patents (e.g., controlled‑release tablets, novel delivery systems) expired in the 2019‑2022 range.

3. Manufacturing‑process patents (e.g., a new synthetic route) can survive longer. The example above (US 9,123,456) is scheduled to expire in 2028, which means a manufacturer could still claim a unique production method until that time.

4. Generic availability

   • In the United States, the first generic avanafil (Stendra‑like) received FDA approval in 2021.
   • In the European Union and most other major markets, generics entered the market around 2022‑2024.

5. Patent status varies by jurisdiction

   • The expiration dates above are for U.S. patents. European patents often expire a few months later, and some countries may still have additional regional patents covering specific formulations or packaging.
   • Always check the national patent office database for the most up‑to‑date status in your country.

Practical Bottom Line

• For most consumers in 2026, Stendra is no longer under exclusive patent protection in the U.S.
• Generic versions are widely available, typically at a lower cost.
• If you’re a manufacturer looking to produce avanafil, you can no longer rely on the old patents that covered composition and use, but you may still need to consider newer manufacturing‑process patents that are still active.

If you need precise patent information for a specific market or a particular formulation, it’s best to consult a patent attorney or the national patent database.